New developments in angiogenesis: A major mechanism for tumor growth and target for therapy

Cancer Journal from Scientific American

Volumn 4, Issue 4, 1998, Pages 209-217

  Jones, Adam ^a   Harris, Adrian L ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; INTEGRIN; INTERLEUKIN 12; LIGAND; MARIMASTAT; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53; ROQUINIMEX; SURAMIN; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CLINICAL TRIAL; DRUG MECHANISM; ENDOTHELIUM CELL; ENTEROPATHY; EXTRACELLULAR MATRIX; FATIGUE; GENE THERAPY; HUMAN; HYPOXIA; INFLAMMATORY CELL; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PEPTIDE HYDROLASES; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031927962     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Bicknell R, Lewis CE, Ferrara N. Tumor angiogenesis. Oxford: Oxford University Press, 1997.
4. Zhang H-T, Craft P, Scott P et al. Enhancement of tumor growth and vascularity by transfection of vascular endothelial growth factor into MCF-7 breast carcinoma cells. J Natl Cancer Inst 1995; 87:213-218.
5. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of c6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996;56:393-401.
6. Fox SB, Gatter KC, Bicknell R et al. Relationship of EC proliferation to tumor vascularity in human breast cancer. Cancer Res 1993;53:4161-4163.
7. Jeltsch M, Kaipainen A Joukov V et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423-1425.
8. Achen MG, Jeltsch M, Kukk E et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2(Flk1) and VEGF receptor 3 (FLK4). Proc Natl Acad Sci USA 1998;95:548-553.
9. Soker S, Takashima S, Miao HQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-745.
10. Sato TN, Tazowa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-74.
11. Suri C, Jones PF, Patan S et al. Requisite role of angiopoietin-1, a ligand for the Tie-2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-1180.
12. Vikkula M, Boon LM, Carraway KL III et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase Tie-2. Cell 1996;87:1181-1190.
13. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
14. Moghaddam A, Zhang H-T, Fan T-PD et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:998-1002.
15. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 1997;78:672-677.
16. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-SRC exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-6165.
17. Dameron K, Volpert O, Tainsky M et al. Control of angiogenesis by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
18. Dawson DW, Pearce SFA, Zhong R et al. CD 36 mediates the in vitro effects of thrombospondin-1 on ECs. J Cell Biol 1997;138: 707-717.
19. O'Reilly MS, Holmgren L, Chen CC et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
20. Cao Y, Chen A, An SSA et al. Kringle 5 of plasminogen is a novel inhibitor of EC growth. J Biol Chem. 1997;272:22924-22928.
21. D'Angelo G, Struman I, Martial J et al. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary ECs is inhibited by the antiangiogenic factor 16-kd N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995;92:6374-6378.
22. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
23. Boehm T, Folkman J, Browder T et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
24. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF, VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575.
25. Arbiser JL, Moses MA, Fernandez CA et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997;94:861-866.
26. Sullivan C, Lewis CE, Harris AL et al. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993;342:148-149.
27. Ciardiello F, Damiano V, Bianco R et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996;88:1770-1776.
28. Stellmach V, Volpert OV, Crawford SE et al. Tumor suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer 1996;32A:2394-2400.
29. Levy AP, Levy NS, Iliopoulous O et al. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 1997;51: 575-578.
30. An WG, Kanelka M, Simon MC et al. Stabilization of wild-type p53 by hypoxia-inducible factor-1α. Nature 1998;392:405-408.
31. Mukhopadhyay D, Tsiokas L, Zhou X-M et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995;375:577-581.
32. Hanahan D, Christofori G, Naik P et al. Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A:2386-2393.
33. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumor cells and ECs: the "angiogenesis progression" hypothesis. Eur J Cancer. 1996;32A:2438-2450.
34. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
35. Leek RD, Lewis CE, Whitehouse R et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-4629.
36. Min HY, Doyle LV, Vitt CR et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-2433.
37. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451-2460.
38. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996; 32A:2423-2429.
39. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct αν integrins. Science 1995;270: 1500-1502.
40. Brooks PC, Silletti S, von Schalscha TL et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
41. Denekamp J. Vasculature as a target for tumor therapy. Prog Appl Microcirculation 1984;4:28-44.
42. Huang X, Molema G, King S et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-550.
43. Devore RF, Hellerqvist CG, Wakefield GB et al. Phase 1 study of the antineovascularization drug CM 101. Clin Cancer Res 1997;3: 365-372.
44. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380.
45. Kong H-L, Crystal RG. Gene therapy strategies for tumor angiogenesis. J Natl Cancer Inst 1998;90:273-286.
46. Millauer B, Longhi MP, Plate KH, et al. Dominant negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56:1615-1620.
47. Jagger RT, Chan HY, Harris AL et al. EC-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum Gene Ther 1997;8:2239-2247.
48. Dachs GU, Patterson AV, Firth JD et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997;3:515-520.
49. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998;338:991-992.
50. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15:39-48.
51. O'Brien T, Cranston D, Fuggle S et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510-513.
52. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
53. Chung YS, Maeda K, Sowa M. Prognostic value of angiogenesis in gastro-intestinal tumors. Eur J Cancer 1996;32A;2501-2505.
54. Horak ER, Leek R, Klenk N et al. Angiogenesis, assessed by platelet/EC adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-1124.
55. Fox SB, Westwood M, Moghaddam A et al. The angiogenic factor platelet-derived EC growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer. 1996;73:275-280.
56. Weidner N, Sample JP, Welch WR. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
57. Macchiarini P, Hardin MJ, Fontanini G et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340:145-146.
58. Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischaemic diseases. Thromb Haemost 1997;78:678-683.